Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the sixteen brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $130.33.
A number of equities research analysts have issued reports on NKTR shares. JPMorgan Chase & Co. initiated coverage on Nektar Therapeutics in a research report on Friday, August 21st. They issued a "neutral" rating and a $65.00 price target on the stock. Wedbush cut their target price on shares of Nektar Therapeutics from $80.00 to $50.00 and set a "neutral" rating on the stock in a research note on Wednesday, September 23rd. UBS Group assumed coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They issued a "neutral" rating and a $53.00 price target for the company. TD Cowen raised shares of Nektar Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Finally, Leerink Partners assumed coverage on shares of Nektar Therapeutics in a research report on Monday, October 12th. They set an "outperform" rating and a $130.00 price objective for the company.
Check Out Our Latest Analysis on Nektar Therapeutics
Key Stories Impacting Nektar Therapeutics
Here are a few of the latest stories about NKTR:
- Positive Sentiment: HC Wainwright raised its EPS estimates across several periods, including FY2026 and FY2027, while maintaining a Buy rating and $185 price target. Its revisions imply smaller projected losses in the near term and higher FY2030 EPS of $0.59, which could support investor optimism. Nektar Therapeutics analyst coverage
- Neutral Sentiment: CEO Howard Robin and insider Jonathan Zalevsky sold 429 and 192 shares, respectively. Both transactions were disclosed as covering tax withholding on vested equity awards, and each represented less than 3% of the seller’s holdings, making them less concerning than discretionary insider sales. CEO transaction filing
Nektar Therapeutics Trading Down 5.5%
NKTR opened at $32.54 on Friday. The firm has a market capitalization of $1.11 billion, a PE ratio of -5.04 and a beta of 1.44. Nektar Therapeutics has a twelve month low of $32.51 and a twelve month high of $109.00. The firm's 50-day moving average price is $45.39 and its 200 day moving average price is $64.50.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating analysts' consensus estimates of ($2.07) by $0.44. Nektar Therapeutics had a negative return on equity of 29.31% and a negative net margin of 339.67%. The company had revenue of $9.39 million for the quarter, compared to the consensus estimate of $10.27 million. As a group, analysts predict that Nektar Therapeutics will post -7.39 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Nektar Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in NKTR. Virtu Financial LLC purchased a new stake in shares of Nektar Therapeutics in the 3rd quarter worth about $867,000. Aquatic Capital Management LLC acquired a new stake in Nektar Therapeutics during the third quarter worth approximately $697,000. Goldman Sachs Group Inc. raised its holdings in Nektar Therapeutics by 171.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 621,249 shares of the biopharmaceutical company's stock valued at $37,614,000 after acquiring an additional 392,759 shares during the last quarter. K2 Principal Fund L.P. lifted its stake in shares of Nektar Therapeutics by 41.7% during the 3rd quarter. K2 Principal Fund L.P. now owns 106,939 shares of the biopharmaceutical company's stock worth $6,474,000 after purchasing an additional 31,474 shares during the period. Finally, 49 Wealth Management LLC acquired a new stake in shares of Nektar Therapeutics during the third quarter worth $351,000. 75.88% of the stock is owned by institutional investors and hedge funds.
About Nektar Therapeutics
(
Get Free Report)
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.